Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : Nvo save search
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides
Published: 2022-09-23 (Crawled : 06:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
|
| O: 5.45%
H: 0.0%
C: -8.46%
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: -0.53%
H: 0.81%
C: 0.14%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -1.69%
H: 0.0%
C: 0.0%
IPHA | $2.46 3.8% 4.05% 690
|
Health Technology
|
| O: -2.02%
H: 0.41%
C: -3.72%
ongoing pharma trial phase 2
Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes
Published: 2022-08-22 (Crawled : 12:00) - globenewswire.com
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: 3.78%
H: 0.49%
C: -0.88%
trial diabetes phase 2
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
Published: 2022-06-03 (Crawled : 08:00) - biospace.com/
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: -0.32%
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: 0.65%
H: 0.63%
C: 0.16%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
IPHA | $2.46 3.8% 4.05% 690
|
Health Technology
|
| O: 2.96%
H: 0.98%
C: -1.15%
AZN | News | $71.2 0.49% 0.46% 300K
|
Health Technology
|
| O: -0.56%
H: 0.82%
C: -0.64%
iph5201 pharma cancer phase 2
Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers
Published: 2021-12-16 (Crawled : 09:00) - biospace.com/
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
|
| O: -5.02%
H: 5.6%
C: 0.96%
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: 2.6%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 1.91%
H: 0.0%
C: 0.0%
IPHA | $2.46 3.8% 4.05% 690
|
Health Technology
|
| O: -1.27%
H: 1.68%
C: 0.5%
iph6101 blood trial phase 1 cancer phase 2
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-07-21 (Crawled : 13:00) - biospace.com/
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: 0.9%
H: 0.72%
C: 0.58%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 0.58%
H: 0.42%
C: 0.38%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -2.13%
disease liver disease treatment phase 1 results liver trial phase 2 phase 3
Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia
Published: 2021-07-06 (Crawled : 06:00) - globenewswire.com
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: 1.54%
H: 0.03%
C: -0.23%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -1.0%
H: 0.1%
C: -0.25%
IPHA | $2.46 3.8% 4.05% 690
|
Health Technology
|
| O: -3.41%
H: 2.32%
C: -0.59%
covid phase 2 trial covid-19
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-06-22 (Crawled : 12:15) - biospace.com/
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: -0.39%
H: 0.27%
C: -0.21%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: 0.08%
H: 1.01%
C: 0.9%
disease liver disease treatment phase 2 liver trial
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M
|
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.